Antiviral Drug Resistance: Mechanisms and Clinical Implications
- 30 September 2010
- journal article
- correction
- Published by Elsevier BV in Infectious Disease Clinics of North America
- Vol. 24 (3), 809-833
- https://doi.org/10.1016/j.idc.2010.07.001
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyJournal of Hepatology, 2009
- Understanding the molecular basis of HBV drug resistance by molecular modelingAntiviral Research, 2008
- Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis BHepatology International, 2008
- Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locusJournal of Clinical Virology, 2008
- Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal modelsAntiviral Research, 2008
- A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxisJournal of Hepatology, 2008
- Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfectionLiver Transplantation, 2007
- Infection of a human hepatoma cell line by hepatitis B virusProceedings of the National Academy of Sciences of the United States of America, 2002
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationThe New England Journal of Medicine, 1999
- Progressive Disease Due to Ganciclovir-Resistant Cytomegalovirus in Immunocompromised PatientsThe New England Journal of Medicine, 1989